Filtered By:
Source: The American Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 336 results found since Jan 2013.
Frequency, Trends and Outcomes of Cerebrovascular Events Associated with Atrial Fibrillation Hospitalizations
Atrial Fibrillation (AF) is the leading heart rhythm disorder with lifetime risk as high as 1 in 3 people across the world, contributing significantly to the risk of stroke, heart failure and mortality.1, 2 The incidence and prevalence of AF continue to increase for many reasons including, but not limited to the aging population in the Unites States and the newer technological modalities such as smartwatch detecting AF early among asymptomatic patients.3, 4 It is well established that AF is an independent risk factor for stroke as demonstrated by the Framingham study, and in recent times has been implicated in cryptogenic strokes.
Source: The American Journal of Cardiology - October 12, 2020 Category: Cardiology Authors: Rajkumar Doshi, Devina Adalja, Ashish Kumar, Mihir Dave, Mariam Shariff, Jay Shah, Nageshwara Gullapalli, Rupak Desai, Chintan Rupareliya, Yasar Sattar, Saraschandra Vallabhajosyula Source Type: research
Dose of Direct Oral Anticoagulants and Adverse Outcomes in Asia
One of the main purposes in the treatment of patients with atrial fibrillation (AF) is the prevention of stroke or systemic embolism. In the current clinical practice, direct oral anticoagulants (DOACs) have been approved for thromboembolism prevention in patients with non-valvular atrial fibrillation (NVAF). Each DOAC has specific dose reduction criteria considering age, renal function, body weight, and concomitant medications. A previous report from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II [ORBIT-AF II] showed that a significant minority (almost 1 in 8) of U.S.
Source: The American Journal of Cardiology - October 12, 2020 Category: Cardiology Authors: Junichi Ohno, Yohei Sotomi, Akio Hirata, Yasushi Sakata, Atsushi Hirayama, Yoshiharu Higuchi Source Type: research
Frequency, Trends, and Outcomes of Cerebrovascular Events Associated With Atrial Fibrillation Hospitalizations
Atrial Fibrillation (AF) is the leading heart rhythm disorder with lifetime risk as high as 1 in 3 people across the world, contributing significantly to the risk of stroke, heart failure and mortality.1,2 The incidence and prevalence of AF continue to increase for many reasons including, but not limited to the aging population in the Unites States and the newer technological modalities such as smartwatch detecting AF early among asymptomatic patients.3,4 It is well established that AF is an independent risk factor for stroke as demonstrated by the Framingham study, and in recent times has been implicated in cryptogenic strokes.
Source: The American Journal of Cardiology - October 12, 2020 Category: Cardiology Authors: Rajkumar Doshi, Devina Adalja, Ashish Kumar, Mihir Dave, Mariam Shariff, Jay Shah, Nageshwara Gullapalli, Rupak Desai, Chintan Rupareliya, Yasar Sattar, Saraschandra Vallabhajosyula Source Type: research
Relation of Interatrial Block to Cognitive Impairment in Patients ≥ 70 Years of Age (From the CAMBIAD Case-Control Study)
The association between atrial fibrillation, stroke, and interatrial block (IAB) (P-wave duration ≥120 ms) is well recognized, particularly in the case of advanced IAB. We aimed to assess the association of IAB with mild cognitive impairment. CAMBIAD (Advanced Characterization of Cognitive Impairment in Elderly with Interatrial Block) was a case-control multicenter study, conducted in subjects aged ≥70 years in sinus rhythm without significant structural heart disease. Diagnosis of mild cognitive impairment was performed by an expert geriatrician, internist, or neurologist in the presence of changes in cognitive functi...
Source: The American Journal of Cardiology - September 14, 2020 Category: Cardiology Authors: Cristian Herrera, Vanesa Bru ña, Pedro Abizanda, Pablo Díez-Villanueva, Francesc Formiga, Rosa Torres, José Carreras, Rocio Ayala, F. Javier Martin-Sánchez, Antoni Bayés-Genis, Roberto Elosua, Antonio Bayés-de-Luna, Manuel Martínez-Sellés, CAMBIAD Source Type: research
Comparison in Patients < 75 Years of Age - vs – Those > 75 Years on One-Year-Events with Atrial Fibrillation and Left Atrial Appendage Occluder (From the Prospective Multicenter German LAARGE Registry)
Left atrial appendage closure (LAAC) is an alternative to oral anticoagulation therapy in patients with non-valvular atrial fibrillation for the prevention of embolic stroke and systemic embolism. Although elderly patients (>75 years) have both higher ischemic and bleeding risk as compared to younger patients, they benefit from optimal anticoagulation. The sub-analysis aimed to assess the indications, the safety, efficacy, and 1-year outcomes of interventional LAAC in elderly patients ( ≥ 75 years) compared to younger (
Source: The American Journal of Cardiology - September 13, 2020 Category: Cardiology Authors: Aref El Nasasra, Johannes Brachmann, Thorsten Lewalter, Ibrahim Akin, Horst Sievert, Christoph A. Nienaber, Christian Wei ß, Sven T. Pleger, Hüseyin Ince, Jens Maier, Stephan Achenbach, Holger H. Sigusch, Matthias Hochadel, Steffen Schneider, Jochen Sen Source Type: research
Comparison in Patients < 75 Years of Age - Versus – Those > 75 Years on One-year-Events With Atrial Fibrillation and Left Atrial Appendage Occluder (From the Prospective Multicenter German LAARGE Registry)
Left atrial appendage closure (LAAC) is an alternative to oral anticoagulation therapy in patients with non-valvular atrial fibrillation for the prevention of embolic stroke and systemic embolism. Although elderly patients (>75 years) have both higher ischemic and bleeding risk as compared with younger patients, they benefit from optimal anticoagulation. The subanalysis aimed to assess the indications, the safety, efficacy, and 1-year outcomes of interventional LAAC in elderly patients ( ≥ 75 years) compared with younger (
Source: The American Journal of Cardiology - September 13, 2020 Category: Cardiology Authors: Aref El Nasasra, Johannes Brachmann, Thorsten Lewalter, Ibrahim Akin, Horst Sievert, Christoph A. Nienaber, Christian Wei ß, Sven T. Pleger, Hüseyin Ince, Jens Maier, Stephan Achenbach, Holger H. Sigusch, Matthias Hochadel, Steffen Schneider, Jochen Sen Source Type: research
Network Meta-analysis Comparing Apixaban versus Rivaroxaban in Morbidly Obese Patients with Atrial Fibrillation
The efficacy and safety of DOACs in morbidly obese patients have been well investigated over the last few years.1-4 Our recent meta-analysis showed that the DOAC group did not increase stroke or systemic embolism (SE) event rate compared to the warfarin group and the DOAC use was significantly associated with a lower major bleeding event rate compared to the warfarin group.5 However, it is still unknown which DOAC is more appropriate than others. Apixaban and rivaroxaban are the two most common DOACs prescribed in the U.S but there is no guidance on which agent should be selected in morbidly obese patients with AF.
Source: The American Journal of Cardiology - September 7, 2020 Category: Cardiology Authors: Kazuhiko Kido, Mikiko Shimizu, Tsuyoshi Shiga, Masayuki Hashiguchi Source Type: research
Prognostic Implications of Significant Isolated Tricuspid Regurgitation in Patients With Atrial Fibrillation Without Left-Sided Heart Disease or Pulmonary Hypertension
The prognostic impact of isolated tricuspid regurgitation (TR) in patients with atrial fibrillation (AF) has not been investigated. The purpose of this study was to investigate the prognostic implications of significant isolated TR in AF patients without left-sided heart disease, pulmonary hypertension or primary structural abnormalities of the tricuspid valve.A total of 63 AF patients with moderate and severe TR were matched for age and gender to 116 AF patients without significant TR. Patients were followed for the occurrhttps://doi.org/10.13039/100006520ence of all-cause mortality, hospitalization for heart failure and stroke.
Source: The American Journal of Cardiology - August 27, 2020 Category: Cardiology Authors: Marlieke F Dietz, Laurien Goedemans, N Mai Vo, Edgard A Prihadi, Pieter van der Bijl, Bernard J Gersh, Nina Ajmone Marsan, Victoria Delgado, Jeroen J Bax Source Type: research
Comparison of Frequency of Atrial Fibrillation in Blacks versus Whites and the Utilization of Race in a Novel Risk Score
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia in the world, with over 30 million people affected as of 2010.1 The number of patients projected to develop AF will double over the next decade.2 AF is independently associated with an increased risk of stroke,3 heart failure (HF),4 and mortality.5 It is not surprising, thus, that AF assumes a sizeable share of health care expenditure and its magnitude is reaching epidemic proportions.6 Blacks despite having a higher prevalence of traditional risk factors for AF, such as HF, hypertension, and diabetes mellitus, have been shown to have a lower incidence of AF.
Source: The American Journal of Cardiology - August 27, 2020 Category: Cardiology Authors: Gurukripa N. Kowlgi, Sampath Gunda, Santosh K. Padala, Jayanthi N. Koneru, Abhishek J. Deshmukh, Kenneth A. Ellenbogen Source Type: research
Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events
Atrial fibrillation (AF) is strongly linked to chronic kidney disease (CKD) and both of these conditions contribute to poor cardiovascular outcomes. We evaluated the impact of renal failure on major adverse cardiovascular events (MACE) in AF, and predictive value of the 2MACE score in this post-hoc analysis of the AMADEUS trial. The primary endpoint was MACE (composite of myocardial infarction, cardiac revascularisation and cardiovascular mortality). Secondary endpoints included the composite of stroke, major bleeding and non-cardiovascular mortality, and each of the specific outcomes separately.
Source: The American Journal of Cardiology - July 10, 2020 Category: Cardiology Authors: Wern Yew Ding, Gregory Y.H. Lip, Daniele Pastori, Alena Shantsila Source Type: research
Impact of Diabetes Mellitus on Stroke and Survival in Patients with Atrial Fibrillation
Although diabetes mellitus (DM) has been established as a risk factor for developing atrial fibrillation (AF) and is a known risk factor for stroke, it is unclear whether the presence or duration of DM is the primary adverse influence on the clinical course of AF. We retrospectively analyzed patients diagnosed with incident AF to examine the impact of DM on ischemic stroke and all-cause mortality. The diagnosis of DM was established by ICD-9 codes and review of medical records. To account for the significant differences in baseline characteristics of patients with and without diabetes, we matched 909 AF patients with DM wi...
Source: The American Journal of Cardiology - June 28, 2020 Category: Cardiology Authors: Sri Harsha Patlolla, Hon-Chi Lee, Peter A. Noseworthy, Waldemar E. Wysokinski, David O. Hodge, Eddie L. Greene, Bernard J. Gersh, Rowlens M. Melduni Source Type: research
A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients without Atrial Fibrillation
Patients without atrial fibrillation (AF) constitute approximately 75% of patients with thromboembolic events (TE: ischemic stroke, transient ischemic attack (TIA), and systemic embolism)1 but evidence supporting risk stratification and prophylactic treatment in these patients is sparse. The latter may be explained by the lack of an intervention that, beyond treatment of hypertension and cholesterol, reduces TE risk in patients without AF. However, the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial, that almost exclusively included patients without AF, showed that the combination of asp...
Source: The American Journal of Cardiology - June 26, 2020 Category: Cardiology Authors: Kamilla Steensig, Kevin K W Olesen, Morten Madsen, Troels Thim, Lisette Okkels Jensen, Morten W ürtz, Steen Dalby Kristensen, Hans Erik Bøtker, Gregory Y H Lip, John William Eikelboom, Michael Maeng Source Type: research
Comparison of Oral Anticoagulant Use and Stroke Risk among Older Adults Newly-Diagnosed Atrial Fibrillation Living in Urban-vs-Rural Areas
We aimed to assess the association between urban/rural residence and the risk of ischemic stroke in individuals with newly diagnosed atrial fibrillation (AF), and to quantify the role of oral anticoagulation (OAC) initiation in the variation in stroke risk between urban and rural residents with AF. Using 5% random samples of Medicare claims, we identified fee-for-service beneficiaries who were diagnosed with AF between January 2014 and December 2015. Beneficiaries were followed for 1 year since their AF diagnosis, and were categorized according to their initiation of OAC within the year.
Source: The American Journal of Cardiology - June 15, 2020 Category: Cardiology Authors: Jingchuan Guo, Meiqi He, Jared W Magnani, Maria M Brooks, Walid F. Gellad, Inmaculada Hernandez Source Type: research
Baseline CHADS2 Score and Risk of Cardiovascular Events in the Population without Atrial Fibrillation
The association between CHADS2 score and stroke has been confirmed in patients with atrial fibrillation. But the majority of cardiovascular events occurred primarily in population without atrial fibrillation. Therefore, we performed this cohort study to evaluate the association between baseline CHADS2 score and cardiovascular events in the population without atrial fibrillation. A total of 99,755 Chinese adults with complete baseline data were followed for up to 10 years. The primary outcomes were cardiovascular event (a composite endpoint of myocardial infarction, cerebral infarction and cerebral hemorrhage) and all-cause death.
Source: The American Journal of Cardiology - June 2, 2020 Category: Cardiology Authors: Chunpeng Ji, Shouling Wu, Jihong Shi, Zhe Huang, ShuohuaChen, Guodong Wang, Wei Cui Source Type: research
Comparison of the Effect of Atrial Fibrillation Detection Algorithms in Patients with Cryptogenic Stroke Using Implantable Loop Recorders
Occult atrial fibrillation (AF) can be the underlying cause for cryptogenic stroke (CS). Implantable loop recorders (ILRs) have become an important tool for long-term arrhythmia monitoring in CS patients. Office-based ILR implantation by non-electrophysiologist physicians is increasingly common. To report the real world diagnostic yield and accuracy of remote ILR monitoring in high risk CS patients, we retrospectively analyzed 145 consecutive patients with CS who underwent ILR implantation between October 2014 and October 2018 at New York University Langone Health.
Source: The American Journal of Cardiology - May 21, 2020 Category: Cardiology Authors: Ehud Chorin, Connor Peterson, Edward Kogan, Chirag Barbhaiya, Anthony Aizer, Douglas Holmes, Scott Bernstein, Michael Schole, Harish Duraiswami, Michael Spinelli, David Park, Larry Chinitz, Lior Jankelson Source Type: research
